Elutia, Inc.(NASDAQ:ELUT)

Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.